Online Articles: Clinical and Laboratory ObservationsResponse of Relapsed Pancreatoblastoma to a Combination of Vinorelbine and Oral CyclophosphamideDhamne, Chetan MD*,†; Herzog, Cynthia E. MD‡Author Information *Khoo Teck Puat—National University Children’s Medical Institute, National University Health System †Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore ‡The University of Texas MD Anderson Cancer Center, Houston, TX The authors declare no conflict of interest. Reprints: Cynthia E. Herzog, MD, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Pediatrics Unit 87, Houston, TX 77030 (e-mail: email@example.com). Received September 25, 2014 Accepted April 23, 2015 Journal of Pediatric Hematology/Oncology: August 2015 - Volume 37 - Issue 6 - p e378-e380 doi: 10.1097/MPH.0000000000000375 Buy Metrics Abstract Pancreatoblastoma is a rare tumor of the pancreas in children, with favorable prognosis if completely resected. If unresectable, neoadjuvant chemotherapy with cisplatin-based regimens are commonly used with good response that allows for resection. For locally aggressive or metastatic disease, neoadjuvant chemotherapy has been reported. Treatment for relapsed or refractory cases is based on anecdotal experiences. We report 2 cases of relapsing pancreatoblastoma with clinical and radiologic response to vinorelbine and cyclophosphamide. Although cure was not achieved, this combination can be offered as an easily tolerated alternative to aggressive chemotherapy for relapsed cases in a palliative setting. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.